8-K: Femasys Secures Up to $10 Million in Flexible Equity Financing from Alumni Capital LP

Femasys Inc. has entered into an Any Market Purchase Agreement with Alumni Capital LP, providing the company with the right to sell up to $10 million of its common stock through a series of flexible purchases.

Summary

• Femasys Inc. (the 'Company') has entered into an Any Market Purchase Agreement (the 'Purchase Agreement') with Alumni Capital LP (the 'Purchaser') on June 30, 2025.
• The agreement grants Femasys the right, but not the obligation, to sell up to an aggregate of $10 million of its common stock to Alumni Capital LP.
• The term of the Purchase Agreement extends through the earlier of December 31, 2026, the full purchase of the $10 million investment amount, cessation of trading on an Eligible Market, or commencement of certain bankruptcy proceedings.
• Femasys can initiate purchases in series, choosing between two pricing options: (1) up to $1 million (or $5 million by mutual agreement) at 90% of the lowest traded price over the four previous business days, or (2) up to the lesser of $1 million or 100% of the average daily trading volume over the two previous business days at 97% of the lowest daily volume-weighted average price (VWAP) over the two previous business days (or one day by mutual agreement).
• The Company will pay Alumni Capital LP a commitment fee equal to 2% of the $10 million Investment Amount, totaling $200,000, which Femasys expects to pay in cash within five business days of the agreement date.
• Femasys is required to file or confidentially submit a registration statement on Form S-1 covering the offering and sale of the shares by July 30, 2025, and use commercially reasonable efforts to have it declared effective within 120 days.
• The Company cannot issue shares under the agreement that would exceed 19.99% of its total outstanding common stock immediately prior to the agreement's execution (the 'Exchange Cap'), unless stockholder approval is obtained or a legal opinion confirms such approval is not required.
• The Purchaser is prohibited from beneficially owning more than 4.99% of the outstanding common stock, though this limit can be increased to 9.99% upon notice to the Company.

Sentiment

Score: 7

Explanation: The agreement provides Femasys with a crucial source of flexible capital, which is positive for its financial stability and operational runway. While it introduces potential dilution and a discount on share sales, these are common trade-offs for this type of financing. It's a standard strategic move for a company seeking to manage its liquidity and fund future initiatives, indicating a proactive approach to capital management rather than distress or exceptional performance.

Positives

• Secures access to up to $10 million in capital, providing financial flexibility and liquidity for Femasys Inc.
• The agreement offers the Company discretion to draw funds based on market conditions and its financing needs, rather than a fixed schedule.
• The ability to choose between two pricing options allows Femasys to optimize the sale price of its shares.
• The expected payment of the commitment fee in cash avoids immediate additional share dilution from the fee itself.

Negatives

• Potential for significant shareholder dilution as shares are sold at a discount (90% or 97%) to market prices.
• The 2% commitment fee ($200,000) represents a direct cost for securing the financing facility.
• The requirement to file a registration statement and maintain its effectiveness incurs legal and administrative costs.
• The Exchange Cap and Beneficial Ownership Limitation may restrict the speed or total amount of capital that can be raised without further shareholder approval or adjustments.

Risks

• Market conditions and the trading price of the Common Stock will influence the Company's decision to make sales under the Purchase Agreement, potentially limiting the amount or timing of capital raised.
• The availability of other sources of financing may impact the Company's reliance on this agreement.
• Actual results could differ materially from forward-looking statements due to risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering.
• General risks and uncertainties disclosed in the Company's annual report on Form 10-K for the fiscal year ended December 31, 2024, particularly those in the 'Risk Factors' section, could affect the Company's performance and ability to utilize this financing.

Future Outlook

Femasys Inc. expects to consider prevailing market conditions, the trading price of its common stock, and the availability of other financing sources when deciding whether to make sales under the Purchase Agreement. The Company is committed to filing a registration statement on Form S-1 by July 30, 2025, and will use commercially reasonable efforts to ensure its effectiveness within 120 days, with plans to register shares on Form S-3 when available.

Management Comments

• "The Company expects to consider market conditions, the trading price of the Common Stock, and the availability of other sources of financing when determining whether to make sales under the Purchase Agreement."
• "The Company expects to pay the Commitment Fee in cash."

Industry Context

This 'Any Market Purchase Agreement' or 'Equity Line of Credit' is a common financing instrument utilized by publicly traded companies, particularly those in growth phases or with fluctuating capital needs. It provides a flexible, 'at-the-market' mechanism to raise capital over time, avoiding the upfront costs and fixed terms of traditional underwritten offerings. This type of agreement is often favored by companies seeking opportunistic capital raises or those that may not have immediate access to larger, more structured financing options, allowing them to tap into equity markets as needed.

Comparison to Industry Standards

• The structure of this Any Market Purchase Agreement, including the flexible drawdowns and pricing based on market prices (with a discount), is a standard form of equity financing for small to mid-cap public companies, similar to those used by numerous biotech or technology firms seeking ongoing capital for R&D or operational expenses.
• The 2% commitment fee is within the typical range for such facilities, which can vary based on the size of the commitment and the perceived risk of the issuer.
• The 19.99% Exchange Cap without shareholder approval is a common NASDAQ listing rule compliance measure (Rule 5635(d)), ensuring that significant dilution events are subject to shareholder oversight.
• The beneficial ownership limitation for the investor (4.99%, adjustable to 9.99%) is standard to prevent the investor from triggering beneficial ownership reporting requirements (e.g., Schedule 13D) or being deemed an affiliate, which would impose additional trading restrictions.

Stakeholder Impact

• Shareholders: Will experience potential dilution as new shares are issued under the agreement, which could impact per-share earnings and stock price. However, the capital raised can support company operations and growth, potentially benefiting long-term shareholder value.
• Company Operations: The agreement provides a flexible source of capital, enhancing the company's ability to fund ongoing operations, research and development, and strategic initiatives without immediate large-scale debt or a traditional equity offering.
• Creditors: Improved liquidity and financial flexibility from the capital raise may reduce financial risk, potentially benefiting creditors.

Next Steps

• Femasys Inc. will file a Current Report on Form 8-K, including the Purchase Agreement as an exhibit, with the SEC.
• Femasys Inc. will pay the 2% commitment fee ($200,000) to Alumni Capital LP within five business days following June 30, 2025, expected in cash.
• Femasys Inc. must file or confidentially submit a registration statement on Form S-1 covering the offering and sale of shares by July 30, 2025.
• Femasys Inc. will use commercially reasonable efforts to cause the S-1 registration statement to be declared effective by the SEC within 120 days after June 30, 2025.
• Femasys Inc. will register the shares on Form S-3 as soon as that form becomes available.
• Femasys Inc. will consider market conditions, the trading price of its common stock, and the availability of other financing sources when determining whether to make future sales under the Purchase Agreement.

Key Dates

Recommendation

Keywords

Femasys Inc., FEMY, equity financing, capital raise, common stock, investment agreement, dilution, NASDAQ, Alumni Capital LP, SEC filing, 8-K, stock offering, financial flexibility